Rachel Koelmeyer

View Scopus Profile

Research activity per year

If you made any changes in Pure these will be visible here soon.

7 Finished

Health Outcomes of Australian patients with inadequate disease control and clinical correlates of improved disease activity
Hoi, A., Kandane-Rathnayake, R., Koelmeyer, R., Bonin, J. & Morand, E.
16/08/21 → 14/01/22
Project: Research
Lupus Cost Regression Analysis
Hoi, A., Morand, E. & Koelmeyer, R.
GlaxoSmithKline (GSK) Australia
17/12/18 → 16/12/20
Project: Research
Financial Support for the Australian Lupus Registry & Biobank 2017
Morand, E., Koelmeyer, R. & Hoi, A.
10/03/17 → 31/12/17
Project: Research
Evaluation of Definitions of Remission in SLE
Morand, E., Kandane-Rathnayake, R. & Koelmeyer, R.
3/01/17 → 31/12/17
Project: Research
Glucocorticoid- and Nephritis- Associated Morbidity in SLE
Morand, E., Kandane-Rathnayake, R. & Koelmeyer, R.
3/01/17 → 21/12/18
Project: Research

20 Article
3 Abstract
2 Meeting Abstract
1 Letter

Algorithm for calculating high disease activity in SLE
Hoi, A., Nim, H. T., Koelmeyer, R., Sun, Y., Kao, A., Gunther, O. & Morand, E., Sep 2021, In: Rheumatology. 60, 9, p. 4291-4297 7 p.
Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)
Disease course following High Disease Activity Status revealed patterns in SLE
Hoi, A., Koelmeyer, R., Bonin, J., Sun, Y., Kao, A., Gunther, O., Nim, H. T. & Morand, E., Dec 2021, In: Arthritis Research and Therapy. 23, 1, 9 p., 191.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
Vincent, F. B., Kandane-Rathnayake, R., Koelmeyer, R., Harris, J., Hoi, A. Y., MacKay, F., MacKay, F. & Morand, E. F., 15 Jun 2020, In: Lupus Science and Medicine. 7, 1, 9 p., e000375.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
File

6 Citations (Scopus)
High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
Koelmeyer, R., Nim, H. T., Nikpour, M., Sun, Y. B., Kao, A., Guenther, O., Morand, E. & Hoi, A., 27 May 2020, In: Lupus Science and Medicine. 7, 1, 9 p., e000372.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

6 Citations (Scopus)
Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus
Yeo, A. L., Koelmeyer, R., Kandane-Rathnayake, R., Golder, V., Hoi, A., Huq, M., Hammond, E., Nab, H., Nikpour, M. & Morand, E. F., 1 Sep 2020, In: Arthritis Care & Research. 72, 9, p. 1289-1295 7 p.
Research output: Contribution to journal › Article › Research › peer-review

7 Citations (Scopus)

Rachel Koelmeyer

Network

Dive into details

Health Outcomes of Australian patients with inadequate disease control and clinical correlates of improved disease activity

Lupus Cost Regression Analysis

Financial Support for the Australian Lupus Registry & Biobank 2017

Evaluation of Definitions of Remission in SLE

Glucocorticoid- and Nephritis- Associated Morbidity in SLE

Algorithm for calculating high disease activity in SLE

Disease course following High Disease Activity Status revealed patterns in SLE

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus

Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus

Rachel Koelmeyer

Network

Projects

Research output